Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
3.
Drug Alcohol Rev ; 41(6): 1311-1318, 2022 09.
Artículo en Inglés | MEDLINE | ID: covidwho-1879013

RESUMEN

INTRODUCTION: People with substance use disorders are considered a priority group for SARS-CoV-2 vaccination as they are at elevated risk of COVID-19 and its severe complications. However, data are scarce about vaccination coverage in a real-world setting. METHODS: A descriptive study was conducted in people with opioid use disorder (OUD) from three public centres for outpatient drug addiction treatment in Barcelona, Spain, who received brief medical advice and were referred to vaccination clinic sites. RESULTS: Three hundred and sixty-two individuals were included: 277 (77%) were men with a mean age of 48.1 ± 8.9 years and 77% were Spanish. Most (90%) participants engaged in polysubstance use and all individuals were on opioid agonist therapy. Psychiatric comorbidity was present in 56% subjects and 32% individuals had ≥1 chronic disease, 30% had HIV and 13% hepatitis C. There were 258 fully vaccinated individuals (71%; 95% confidence interval [CI] 67, 76). Age (odds ratio [OR] 1.04; 95% CI 1.01, 1.08; P < 0.01) and Charlson Comorbidity Index (OR 1.67; 95% CI 1.11, 2.5; P < 0.01) were associated with full vaccination. The vaccination hesitancy causes cited were complacency (53, 51%), convenience (40, 39%) and confidence (11, 10%). DISCUSSION AND CONCLUSIONS: More than two-thirds of our sample of people with OUD were fully vaccinated. Complacency and convenience represented a significant barrier to complete vaccination among people with OUD on opioid agonist therapy referred to vaccination clinic sites. Additional measures are necessary to increase vaccination, especially for younger individuals and those with less medical comorbidity. Integrating vaccination services in drug outpatient centres could be a useful alternative.


Asunto(s)
COVID-19 , Trastornos Relacionados con Opioides , Adulto , Analgésicos Opioides , COVID-19/prevención & control , Vacunas contra la COVID-19 , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos Relacionados con Opioides/epidemiología , SARS-CoV-2 , España/epidemiología , Vacunación , Cobertura de Vacunación , Vacilación a la Vacunación
6.
Geriatr Nurs ; 42(2): 544-547, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-856716

RESUMEN

The Acute Care for Elders (ACE) is a model of care addressed to reduce the incidence of loss of self-care abilities of older adults occurring during hospitalization for acute illness. This observational study aimed to describe the effectiveness of an ACE unit at a long-term care facility to prevent functional decline (decrease in the Barthel Index score of >5 points from admission to discharge) in older adults with frailty (Clinical Frailty Scale score ≥5) and symptomatic COVID-19. Fifty-one patients (mean age: 80.2 + 9.1 years) were included. Twenty-eight (54.9%) were women, with a median Barthel index of 50 (IQR:30-60) and Charlson of 6(IQR: 5-7), and 33 (64.7%) had cognitive impairment. At discharge, 36(70.6%) patients had no functional decline, 6 (11.7%) were transferred to hospital and 4(7.8%) died. An ACE unit at a long-term care facility constitutes an alternative to hospital care to prevent hospital-associated disability for frail older patients with COVID-19.


Asunto(s)
COVID-19/enfermería , Anciano Frágil , Cuidados a Largo Plazo/organización & administración , Neumonía Viral/enfermería , Anciano , Anciano de 80 o más Años , Femenino , Evaluación Geriátrica , Humanos , Masculino , Neumonía Viral/virología , SARS-CoV-2
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA